This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Mar 2020

Mylan launches first bioequivalent alternative to Advair Diskus in Canada

Myland Pharmaceuticals' Wixela Inhub.

Appropriate asthma and COPD patients provided with a "more affordable alternative to appropriate".

Mylan Pharmaceuticals has launched Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) — the first available bioequivalent alternative to GSK's Advair Diskus in Canada.

Advair Diskus is a leading treatment for asthma and chronic obstructive pulmonary disease (COPD) management. According to IQVIA, it had Canadian sales of $113.9 million for the 12 months ending 31 December 2019.

Wixela Inhub is a dry powder inhaler and is the result of $700 million investment worldwide, including an extensive research and development program. It was approved by Health Canada in January for the twice-daily maintenance treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta2-agonists; or maintenance treatment of COPD.

For asthma patients, Wixela Inhub is available in 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths, whereas for COPD patients, it is available in 250 mcg/50 mcg and 500 mcg/50 mcg strengths.

With today's launch in Canada, Mylan Canada Country Manager David Simpson commented: "We are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients."

Mentioned Companies
Mylan Laboratories Limited
View company profile

Related News